Johnson & Johnson (JNJ) is set to report its fourth-quarter and full-year 2025 results on January 21, 2026. The Zacks Consensus Estimate anticipates fourth-quarter sales of $24.14 billion and earnings of $2.50 per share. For the full year, estimates for 2025 earnings have decreased slightly from $10.87 to $10.83 per share.
J&J’s Innovative Medicine segment is projected to see significant sales driven by key products like Darzalex ($3.74 billion), Tremfya ($1.36 billion), and Erleada ($936 million). However, competition from biosimilars is expected to impact Stelara sales, with an estimate of $1.36 billion. The company’s MedTech segment is expected to report $8.71 billion in sales, though growth may be hampered by challenges in China due to a government procurement program.
J&J has consistently exceeded earnings expectations over the past four quarters, averaging a 3.75% earnings surprise. The company is likely to provide an updated financial outlook for 2026 during the upcoming earnings call, with expectations of over 5% top-line growth for that year.
